Getting overwhelmed by the news is an everyday struggle for those wishing to stay in touch with the latest news. Our newsletter should make it easier for those interested in pharmacovigilance regulations, advancement in the relevant use of artificial intelligence, and personal growth. Approaching with care, the same as we provide PV services, we thoughtfully pick articles every month to keep you updated.
The top 100 applications for LLMs, according to users.
Because of the novelty of advanced therapy medicinal products (ATMPs), pro-active risk management is needed post-authorisation.
New product information wording: extracts from PRAC recommendations on signals adopted at the 10-13 March 2025 PRAC.
And much more...
New product information wording: extracts from PRAC recommendations on signals adopted at the 10-13 March 2025 PRAC
Guidance for healthcare professionals on risk minimisation options for medicines.
Business process description for pharmacovigilance
The top 100 applications for LLMs, according to users.
Generative AI (Gen AI) is already delivering improvements in patient experiences and health outcomes, as well as easing administrative burdens for doctors, nurses and clinicians. With the demand for healthcare outpacing the workforce, healthcare organizations need help from AI tools and automation.
By reverse engineering your team’s workflow, you can customize generic AI tools to fit your processes.
Because of the novelty of advanced therapy medicinal products (ATMPs), pro-active risk management is needed post-authorisation; for example, through implementation of additional risk minimisation measures (aRMMs).
Biochemical drug similarity-based methods demonstrate successes in predicting adverse drug events (ADEs) in preclinical settings and enhancing signals of ADEs in real-world data mining. Despite these successes, drug similarity-based ADE detection shall be expanded with false-positive control and evaluated under a time-to-detection setting.
For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment.
05-07 May 2025 - 14:00 - 18:00
12-16 May 2025 - 14:00 - 18:30
02-06 June 2025 - 9:00 - 13:30
18-20 June 2025 - 9:00 - 13:30
These are the trainings that NextPV representatives will execute in this and the upcoming month.
Pictures used in this newsletter were generated by AI.